Clarity Pharmaceuticals' prostate-cancer diagnostic could be highly differentiated from peers if its Phase 3 trial delivers on sensitivity and specificity, Bell Potter analysts say in a note. They tell clients that revenue timing remains highly uncertain and contingent on multiple factors, but that the Australia-listed clinical-stage radiopharmaceutical company looks to be well funded into FY 2025 and should be self-funding from FY 2026. Bell Potter cuts the stock's target price 7.1% to A$1.30 but maintains a speculative buy rating. ([email protected]; @StuartLCondie)
- Forums
- ASX - By Stock
- Ann: Positive Guidance from FDA on Phase 3 Prostate Cancer Trial
Clarity Pharmaceuticals' prostate-cancer diagnostic could be...
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CU6 (ASX) to my watchlist
|
|||||
Last
$5.89 |
Change
0.040(0.68%) |
Mkt cap ! $1.835B |
Open | High | Low | Value | Volume |
$5.98 | $6.08 | $5.74 | $6.370M | 1.086M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 3474 | $5.89 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$5.90 | 825 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 3474 | 5.890 |
1 | 696 | 5.880 |
1 | 1600 | 5.850 |
2 | 3823 | 5.840 |
1 | 10000 | 5.820 |
Price($) | Vol. | No. |
---|---|---|
5.900 | 825 | 1 |
5.930 | 532 | 1 |
5.940 | 2995 | 1 |
5.980 | 1721 | 1 |
6.000 | 195 | 1 |
Last trade - 16.10pm 17/07/2024 (20 minute delay) ? |
Featured News
CU6 (ASX) Chart |